[
  {
    "ts": null,
    "headline": "Palisade Bio Details PALI-2108 UC, Crohn’s Plans and Cash Runway Into 2029 at Oppenheimer Conference",
    "summary": "Palisade Bio (NASDAQ:PALI) executives outlined the company’s strategic pivot, lead development priorities, and financing position during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference. Company background and strategic pivot Chief Executive Officer J.D. Finley said",
    "url": "https://finnhub.io/api/news?id=05e80d9d65398668387c63f102f3eb1601719b3d393424fee395949a171da2e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772364644,
      "headline": "Palisade Bio Details PALI-2108 UC, Crohn’s Plans and Cash Runway Into 2029 at Oppenheimer Conference",
      "id": 139269509,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Palisade Bio (NASDAQ:PALI) executives outlined the company’s strategic pivot, lead development priorities, and financing position during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference. Company background and strategic pivot Chief Executive Officer J.D. Finley said",
      "url": "https://finnhub.io/api/news?id=05e80d9d65398668387c63f102f3eb1601719b3d393424fee395949a171da2e0"
    }
  }
]